BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo (BLGO) announced that its wholly owned BEST subsidiary is conducting two extended, paid industrial pilots for PFAS treatment. The programs at its Oak Ridge, Tennessee, engineering facility test customer-specific water streams using the Aqueous Electrostatic Concentrator, a water-treatment system. They will inform potential full-scale designs and purchasing decisions. Industrial applications now represent the majority of BEST's commercial opportunity pipeline.
At Lake Stockholm, New Jersey, the system has removed PFAS, or per- and polyfluoroalkyl substances, from drinking water since January 2026; treated water continues to meet New Jersey and EPA standards. BEST is working to add pretreatment to address increased source-water hardness. BioLargo is exploring financial and operating partnerships to accelerate commercialization and expand market reach.
BioLargo (OTCQX:BLGO) has launched the direct-to-consumer website for barebird, the first brand from its BioLargo CPG subsidiary. The company-owned brand's website, www.barebird.com, went live on Friday following an announcement last week.
barebird launched with pet and laundry odor products. BioLargo CPG holds the exclusive license to use BioLargo's CupriDyne technology in consumer-packaged goods. The company plans additional pet and household odor and cleaning products.
BioLargo (BLGO) reported commercial progress at subsidiary Clyra Medical, including ViaCLYR use in hundreds of patients since its March 2026 launch. ViaCLYR is an FDA 510(k)-cleared wound irrigation solution. Clyra is working through evaluations and approval processes with several U.S. healthcare systems; it is farthest along with a system operating almost 20 hospitals and 200 clinics, focused on advanced wound and burn care.
Distributor Advanced Solution provides access to approximately 85% of the U.S. market. Al Hikma covers 18 Middle Eastern countries, where product registrations are underway. Clyra is also preparing an additional product line with a confidential partner, with details expected as commercialization plans advance. BioLargo released a fireside chat about this progress and furnished its transcript as an exhibit to a Form 8-K.
BioLargo (OTCQX:BLGO) launched barebird, a company-owned consumer brand using its CupriDyne technology for pet and household odor elimination.
The company intends to participate more directly in consumer product revenue and build brand equity, while assuming greater marketing and distribution responsibility. BioLargo recognized more than $20 million in revenue under its historical Pooph supply agreement; those results are not projections for barebird.
BioLargo signed agreements with a company led by Jordan Stanley and his Kindness Commerce team, and with Prime Team Agency, both associated with Pooph marketing. Initial pet and laundry odor products are expected at barebird.com in the coming days, with Amazon and TikTok Shop storefronts planned to follow. Subsidiary ONM Environmental will manage manufacturing through its manufacturing arrangements.
BioLargo (BLGO) announced that subsidiary Clyra Medical Technologies will exhibit at SAWC Fall 2026 in Las Vegas on October 15-18.
The Symposium on Advanced Wound Care will take place at Caesars Palace. Clyra will be at Booth 330, and its national launch partner, Advanced Solution, will be at Booth 218. Both booths will introduce clinicians to ViaCLYR, Clyra's FDA 510(k)-cleared wound irrigation solution. Its cleared uses include cleansing, irrigating, moistening and debriding acute and chronic wounds, including first- and second-degree burns.
BioLargo (BLGO) and subsidiary BioLargo Canada have formed an Indigenous-led venture, Tũ Nipi Water Solutions, with Fort McKay Oil Services to deploy advanced water treatment technologies in Alberta’s oil sands region.
The partnership targets treatment of oil sands process water (OSPW), wastewater, and other industrial streams in the Athabasca area, with BioLargo holding a minority stake in Tũ Nipi. Emissions Reduction Alberta has conditionally approved Tũ Nipi’s first grant application supporting a project budget of CAD $4.6 million for commercial trials of BioLargo technologies, which are already underway in northern Alberta. Beyond OSPW, Tũ Nipi and BioLargo Canada have identified potential clients and an initial wastewater project focused on PFAS and odor control solutions. A formal launch event in Fort McMurray is planned for October, with further project details to follow.
BioLargo (BLGO) will host a public townhall, Q2 2026 earnings results webcast, and conference call on Thursday, September 10, 2026, at 1:00 pm Pacific / 4:00 pm Eastern to review financial results for the three months ended June 30, 2026 and discuss recent milestones in an extended Q&A format.
Participants can join via webcast at https://www.webcaster5.com/Webcast/Page/2448/54527 or by teleconference using domestic number 888-506-0062 or international number +1-973-528-0011 with access code 543643. A teleconference replay will be available through Thursday, September 24, 2026 at 877-481-4010 (domestic) or 919-882-2331 (international) with passcode 54527. Investors are encouraged to submit questions in advance via the BioLargo Shareholder Discord and access replay materials on the company’s investor relations website.
BioLargo (BLGO) announced that subsidiary Clyra Medical Technologies has signed an exclusive purchasing and reseller agreement with Spartan Medical to distribute its FDA 510(k)-cleared ViaCLYR™ wound irrigation solution to U.S. government healthcare facilities worldwide.
The deal creates Clyra’s third distribution channel, expanding beyond its existing U.S. commercial distributor Advanced Solutions and an international agreement with Al Hikma covering 18 countries. ViaCLYR, powered by the Clyrasept™ Copper-Iodine Complex Solution (CICS), is described as a broad-spectrum antimicrobial optimized for speed, efficacy, persistence, and biocompatibility. In clinical tests, it killed 99.9999% of 18 pathogens within one minute and provided up to 72 hours of antimicrobial management without reapplication, while remaining non-cytotoxic.
ViaCLYR is now listed on the Defense Logistics Agency’s ECAT system and is available to VA and DoD facilities, the Federal Bureau of Prisons, Indian Health Service, other federal healthcare facilities, and certain civilian hospitals under VA-funded contracts.
BioLargo (OTCQX:BLGO) announced that President and CEO Dennis P. Calvert will present at the inaugural Nasdaq / LD Micro Summit on Wednesday, September 9, 2026, at Nasdaq's San Francisco headquarters. The event will host about 25 public companies presenting to institutional investors.
Each company, including BioLargo, is scheduled for a 15-minute presentation followed by a 15-minute breakout session for Q&A with management. Investors can also request one-on-one meetings with Calvert through conference representatives or by emailing BioLargo's investor relations contact.
BioLargo (OTCQX:BLGO) announced it will participate in Gabelli Funds' 4th Annual PFAS Symposium on September 24, 2026, in New York City. Former U.S. EPA senior executive Sally Gutierrez, a board member of BioLargo subsidiary BEST, will represent the company.
According to BioLargo, its PFAS solution is the patented Aqueous Electrostatic Concentrator (AEC), commercialized through BEST. A commercial reference installation at the Lake Stockholm water facility in New Jersey has operated for more than six months and is monitored under a 12‑month program by the New Jersey Department of Environmental Protection.